Gastrointestinal drug development

ICON has extensive experience in conducting gastrointestinal studies

We work across the entire drug development spectrum. Our experience ranges from the initial studies in Phase I through post-marketing efforts in Phase IV.

ICON Gastrointestinal experience in last five years:

100+
Studies
26,000+
Patients involved
9,000+
Sites

Broad disease experience

ICON's Gastrointestinal team comprises dedicated drug development experts with significant experience conducting clinical trials for experimental therapeutics in the following diseases:

	Diseases
Acid Reflux	Chronic Functional Constipation	Indigestion
Acute Gastric Pain	Crohn’s Disease	Idiopathic Gastroparesis
Acute Pancreatitis	Diarrhea	Inflammatory Bowel Disease
Bowel Prep	Diverticulitis	Irritable Bowel Syndrome
Celiac	Dyspepsia	Irritable Bowel Syndrome with Constipation
Chronic Constipation	Eosinophilic Esophagitis	Irritable Bowel Syndrome with Diarrhea
Colorectal Conditions	Esophagitis	Short Bowel Syndrome
Constipation	Gastroesophageal Reflux	Traveler's Diarrhea
Chronic Idiopathic Constipation	GERD	Ulcerative Colitis

Whitepaper: From genomics to the coming of age glycomics

Glycan biomarkers are quickly becoming key elements of gastrointestinal research, setting the stage for a new golden age of epigenetic research and personalised therapeutics.